Ghaziabad Online

Dermatomycoses Market: Industry trends, Drugs, Companies and Analysis | Anacor Pharmaceuticals, Biolab Farmaceutica, Blueberry Therapeutics, Daewoong Pharmaceutical, Dermala, Helix BioMedix, Novan

 Breaking News
  • No posts were found

Dermatomycoses Market: Industry trends, Drugs, Companies and Analysis | Anacor Pharmaceuticals, Biolab Farmaceutica, Blueberry Therapeutics, Daewoong Pharmaceutical, Dermala, Helix BioMedix, Novan

April 19
22:26 2021
Dermatomycoses Market: Industry trends, Drugs, Companies and Analysis | Anacor Pharmaceuticals, Biolab Farmaceutica, Blueberry Therapeutics, Daewoong Pharmaceutical, Dermala, Helix BioMedix, Novan

Dermatomycoses Market

Dermatomycoses is the medical term for fungal infections of the skin and skin appendages (derma: skin; mykes: fungus) – which encompass nails and hair―caused most commonly by dermatophytes. Fungal infection can happen at any time, and it can be caused due to injured or pathologically changed skin areas.

Dermatophytes are divided into anthropophilic, zoophilic, and geophilic species, according to their transmission route and main occurrence. Anthropophilic dermatophytes prefer humans as the primary host; therefore, transmission from person to person occurs particularly frequently. Around 70% of dermatomycoses in humans are caused by anthropophilic species.

DelveInsight’s “Dermatomycoses Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Dermatomycoses , historical and forecasted epidemiology as well as the Dermatomycoses market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the Dermatomycoses Companies included:

  • Anacor Pharmaceuticals Inc
  • Biolab Farmaceutica Ltda
  • Blueberry Therapeutics Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • TGV-Laboratories
  • Viamet Pharmaceuticals Inc
  • Vyome Biosciences Pvt Ltd
  • And Many Others

 

Get a Sample Copy @ https://www.delveinsight.com/sample-request/dermatomycoses-market

 

Some facts of Dermatomycoses Market:

  • Nenoff et al. (2013) estimated that 91% of the anthropophilic fungus, i.e., T. rubrum, among the dermatophytes caused tinea unguium in Germany.
  • As per Mochizuki et al. (2019), dermatomycoses, including dermatophytosis, is commonly encountered in routine medical care. In Japan, 21.6% of the population was estimated to have tinea pedis, while 10.0% were estimated to have tinea unguium.
  • Fungal infections of the skin are the most frequently occurring infectious diseases, with a worldwide prevalence of 20–25% and high and growing relapse rates. Around 70% of dermatomycoses in humans are caused by anthropophilic species (Euroimmun, n.d.).
  • Shimoyama et al. (2019) estimated that in dermatophytosis, tinea pedis was the most frequent type, followed by tinea unguium (57.4%), tinea corporis (28.3%); tinea cruris (7.3%); tinea manuum (1%); tinea capitus, Celsus’ kerion (0.5%); and tinea barbae (0.02%).

 

Get a Sample Copy @ https://www.delveinsight.com/sample-request/dermatomycoses-market

 

Some of the Dermatomycoses Therapies Included:

  • BB2603
  • SB208
  • And Many Others

 

Request for free sample report @ https://www.delveinsight.com/sample-request/dermatomycoses-market

 

Dermatomycoses may be divided according to the responsible pathogen into dermatophyte, yeast, and mold infections. Fungi on the skin, or dermatophytes, cause dermatophytoses, also referred to as tinea (ringworm). The most common pathogens among children and adolescents are zoophilic dermatophytes. The sources of infection are house pets and, less often, farm animals.

 

Table of Contents:

1. Key Insights

2. Executive Summary of Dermatomycoses

3. Competitive Intelligence Analysis for Dermatomycoses

4. Dermatomycoses : Market Overview at a Glance

5. Dermatomycoses : Disease Background and Overview

6. Patient Journey

7. Dermatomycoses Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Dermatomycoses Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Dermatomycoses : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Dermatomycoses

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Deatiled TOC @ https://www.delveinsight.com/sample-request/dermatomycoses-market

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/dermatomycoses-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share